The global clinical trial third-party logistics market size accounted for USD 5.8 billion in 2025 and is predicted to increase from USD 6.26 billion in 2026 to approximately USD 12.41 billion by 2035, expanding at a CAGR of 7.9% from 2026 to 2035. The growing trial complexities, a shift towards specialized supply chain solutions, expanding clinical trials, growing technological innovations, and rising collaborations are driving the market growth.
Market at a Glance: Key Highlights and Trends
The clinical trial third-party logistics refers to the specialized logistic partners providing supply chain and logistics services for safe and efficient packing, labeling, storage, and distribution of investigational drugs and clinical trial resources. The presence of temperature-controlled storage, inventory management, and regulatory compliance support also drives their demand. Additionally, cold chain management, real-time monitoring, and direct-to-patient deliveries are also increasing their use.
Market Forecast: The Emerging Opportunities
- Expanding decentralized trials or home-based trials are increasing the demand for clinical trial third-party logistics for direct-to-patient deliveries.
- Growing demand for biologics, personalized medicines, and advanced therapies is also increasing their demand.
- The growth in post-marketing studies is also increasing their use for the collection of real-world evidence.
- A rise in the collaboration and outsourcing trends is also increasing their use for regulatory compliance.
- Growing sustainable and ultra-cold chain logistics solutions are also increasing their adoption rates.
The graph represents the total number of clinical trials, recorded in the years 2023 and 2024, globally. It indicates that as the number of clinical trials increases, the demand for logistics support will increase. This, in turn, is fueling the adoption of clinical trial third-party logistics solutions to enhance clinical trials and R&D activities, which ultimately promotes market growth.
Market Segmentation Overview
- By service type, the transportation segment contributed the biggest revenue share of 34% of the clinical trial third-party logistics market in 2025 and a CAGR of 7.50%, due to its faster delivery timelines and advanced tracking system. The growth in the clinical trials also increased their use for cross-border shipments. Temperature-controlled solutions and risk management capabilities also increased their use.
- By temperature range type, the ambient segment held a major revenue share of 38% and a CAGR of 6.80% of the market in 2025, as most of the drugs required ambient temperature for their stability. Their affordability, faster transportation, and simple handling and storage also increased their use. Their widespread availability also increased their use.
- By phase type, the phase III segment led the market with 44% share in 2025 and is expected to expand rapidly with a CAGR of 8.2% during the forecast period, driven by a high volume of drug supply. The complex trial design and regulatory standards also increased their use. The large scale and complex distribution also increased the demand for intensive cold chain requirements.
- By end user, the pharmaceutical companies segment accounted for the highest revenue share of 46% of the clinical trial third-party logistics market in 2025 due to a large pipeline of drugs and high R&D expenditure. The growth in the clinical trial and outsourcing trends has also increased their use. Stringent regulatory compliance requirements also increased their use.
- By therapeutic area type, the oncology segment accounted for the highest revenue share of 36% of the market in 2025 and is expected to grow with the fastest CAGR of 8.7% during the forecast period, due to growth in its incidence rates and clinical trials. The rise in R&D investments and advancements in therapies also increased their use. Growth in the temperature-sensitive rugs and personalized medicines also promoted their use.
Regional Analysis
North America registered its dominance over the global clinical trial third-party logistics market with a share of 38% in 2025, due to the presence of a robust clinical trial infrastructure, healthcare infrastructure, stringent regulations, and robust pharmaceutical and biotech industries. High R&D investments, advanced cold chain capabilities, and early technology adoption also increased the use of third party logistic solutions.
Asia Pacific held 24% share of the clinical trial third-party logistics clinical trial third-party logistics market in 2025 and is expected to expand rapidly with a CAGR of 9.1% during the forecast period, due to expanding healthcare infrastructure, clinical trials, pharmaceutical industries, and outsourcing trends. Growing R&D activities, government support, technological advancements, and expanding cold chain infrastructure are also fueling their demand.
The Market Leaders: Top Companies in the Market
UPS Healthcare dominated the market with its subsidiary Marken, offering a high-touch service model, where DHL Supply Chain was its closest competitor, offering the largest logistics networks globally. FedEx HealthCare Solutions also maintained its position with Life Science centres handling cold chain storage, distribution with regulatory expertise, where Kehne + Nagel also contributed to the market growth by offering a GxP-compliant network.
Segments Covered in the Report
By Service Type
- Transportation
- Air Freight
- Sea Freight
- Road Transport
- Storage & Warehousing
- Ambient Storage
- Cold Chain Storage
- Refrigerated (2–8°C)
- Frozen (-20°C and below)
- Packaging & Labeling
- Primary Packaging
- Secondary Packaging
- Clinical Labeling
- Distribution & Returns Management
- Direct-to-Site Distribution
- Depot Distribution
- Reverse Logistics
- Ancillary Services
- Comparator Sourcing
- Inventory Management
- Regulatory Compliance Support
By Temperature Range
- Ambient
- Refrigerated (2–8°C)
- Frozen (-20°C and below)
- Ultra-Low Temperature (-70°C and below)
By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
By Therapeutic Area
- Oncology
- Infectious Diseases
- Cardiovascular Diseases
- Neurology
- Rare Diseases
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Brazil
- Argentina
- Rest of Latin America
Latin America
- Europe
- Western Europe
- Germany
- Italy
- France
- Netherlands
- Spain
- Portugal
- Belgium
- Ireland
- UK
- Iceland
- Switzerland
- Poland
- Rest of Western Europe
- Eastern Europe
- Austria
- Russia & Belarus
- Türkiye
- Albania
- Rest of Eastern Europe
- Asia Pacific
- China
- Taiwan
- India
- Japan
- Australia and New Zealand
- ASEAN Countries (Singapore, Malaysia)
- South Korea
- Rest of APAC
- MEA
-
- Saudi Arabia
- United Arab Emirates (UAE)
- Qatar
- Kuwait
- Oman
- Bahrain
GCC Countries
- South Africa
- Egypt
- Rest of MEA
